Search Results 1901-1910 of 16086 for Epilepsy (Partial Onset)
Incidence and Effect Duration of Immune Checkpoint Inhibitor ... Diabetic ketoacidosis in the setting of HNF1A-maturity onset diabetes of the young.
Disease duration from ALS symptom onset of motor weakness ≤ 24 months. ALSFRS-R total score ≥ 36 at screening visit. ALSFRS-R Breathing sub-score should ...
... epilepsy. 2. Age 18 – 65. Exclusion Criteria: 1. Patients who have cognitive impairments that would limit their ability toparticipate in the memory testing. 2 ...
Pediatric patients with ongoing seizures and/or neurological abnormalities;; Hemodynamically unstable patients;; Complex clinical situations requiring medical ...
The overall purpose of this research is to understand how ADAD develops in order to eventually provide treatments for this disorder. Each biological child of a ...
About this study. The purposes of the clinical trial are to determine whether the SA4Ag vaccine can prevent postoperative Staphylococcus aureus infections ...
... partial thromboplastin time (PTT) within normal limits (+15%). Patients on ... onset angina within 3 months or unstable angina (angina symptoms at rest) ...
Pembrolizumab has been approved for treatment of patients with melanoma but has not been proven to be safe or helpful in patients with pancreatic cancer and is ...
Patients who are scheduled and considered eligible (according to MRI safety policies) for a clinically-indicated PET/MR epilepsy or dementia study.
Zimmerman, M.D.. Neurosurgeon. Phoenix, AZ. Areas of focus: Epilepsy surgery, Brain tumor surgery, Carotid endarterectomy, Trigeminal neuralgia surgery ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your Annual Fund gift can drive advancements in cancer care.